Biovest International specializes in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. The company is a subsidiary of Accentia Biopharmaceuticals. It has expertise in the area of manufacturing biologics for research and clinical trials. Additionally, the company develops and markets cell culture systems and an automated vaccine manufacturing instrument for production of cell-based materials and therapeutics. Its product BiovaxID, which is used for the treatment of follicular non-Hodgkins lymphoma has been given the fast-track status by the Food and Drug Administration. The company has a staff of trained professionals that specializes in hollow-fiber technology. It is headquartered in Worcester, Mass.